Previous 10 | Next 10 |
As the standard first-line treatment for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, naproxen and other NSAIDs are effective, but can induce ulceration and bleeding of the digestive tract, with much higher incidence in patients, as noted by An...
Aclaris Therapeutics (ACRS) has priced its public offering of 7,042,254 common shares at $17.75/share, for expected gross proceeds of ~$125M.Underwriters' over-allotment is an additional 1,056,338 shares.Closing date is June 14. Jefferies, SVB Leerink and Piper Sandler are acting as joint boo...
Yesterday, Aclaris Therapeutics ([[ACRS]] -8.4%) announced positive data from a Phase 2a study for its JAK inhibitor ATI-1777 in patients with moderate to severe atopic dermatitis ((AD)).The study achieved statistical significance with the primary endpoint of modified Eczema Area and Sev...
Gainers: Aethlon Medical AEMD +425%, Checkpoint Therapeutics CKPT +26%, Adamis Pharmaceuticals ADMP +12%, SCWorx (WORX) +18%, ZIOPHARM Oncology ZIOP +15%.Losers: Atossa Therapeutics ATOS -14%, CEL-SCI CVM -11%, Precipio (PR...
Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...
ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach ATI-1777 was Generally Well Tolerated Data Support Progression to Ph...
WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a...
Millions of people all over the world deal with arthritic pain. In fact, just in the U.S., the Centers for Disease Control and Prevention (CDC), says about 23% of adults are dealing with it. Nearly 24 million are limited with their activities because of it, with about 25% of people reportin...
Aclaris Therapeutics (ACRS): Q1 GAAP EPS of -$0.57 misses by $0.29.Revenue of $1.78M (+26.2% Y/Y) beats by $0.3M.Press Release For further details see: Aclaris Therapeutics EPS misses by $0.29, beats on revenue
Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021 Advancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe Rheumatoid Arthritis in Second Half of 2021 Advancing ATI-450 int...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...